CAC vs CT Angiography vs Stress Test vs ApoB: When Each Test Is Right

Four-panel cardiac imaging comparison (CAC, CTA, stress test, MRI)

Cardiovascular testing is a layered system, not a single test. The coronary calcium score occupies a specific niche — quantifying calcified plaque burden in asymptomatic adults — but is not the right answer for symptomatic chest pain, suspected acute coronary syndrome, evaluation of ischemia, or initial lipid screening. This page maps the major cardiac tests to the questions they actually answer, when CAC is the right tool, and when something else (CCTA, stress testing, ApoB/Lp(a), cardiac MRI) is the better fit.

What Each Test Actually Answers
Coronary Artery Calcium (CAC)
CT Coronary Angiography (CCTA)
Exercise & Pharmacologic Stress Tests
Cardiac MRI
Invasive Cardiac Catheterization
Lipid Markers (ApoB, Lp(a), LDL-C)
Practical Decision Tree
When CAC Isn't the Right Test
Research Papers and References
Connections
Featured Videos

What Each Test Actually Answers

CAC — "How much mature, calcified plaque burden have I accumulated?"
CCTA — "What is the geometry and severity of plaque (calcified and non-calcified) in my coronaries?"
Stress test — "Is plaque obstructing flow enough to cause ischemia under exertion?"
Cardiac MRI — "What is the structure, function, and tissue character of my heart muscle?"
Cardiac catheterization — "What is the gold-standard view of my coronaries, and can I be treated in the same procedure?"
ApoB / Lp(a) / LDL-C — "What is the lipoprotein burden driving plaque formation?"

These are different questions. The right test depends on which question is being asked.

Coronary Artery Calcium (CAC)

Best for: Asymptomatic adults aged 40–75 at intermediate ASCVD risk where the statin decision is uncertain
What it shows: Calcified plaque burden, total Agatston score, vessel distribution, age/sex percentile
What it misses: Soft (non-calcified) plaque, vulnerable plaque, microvascular disease, electrical conduction issues
Cost: $99–$200 cash; rarely covered by insurance
Radiation: ~1 mSv (similar to a mammogram)
Time: 10 minutes
No prep, no contrast, no IV

CT Coronary Angiography (CCTA)

Best for: Symptomatic patients with low-to-intermediate pretest probability of CAD; younger patients with strong family history; patients with elevated Lp(a) where soft-plaque burden matters
What it shows: Detailed coronary anatomy, plaque composition (soft vs calcified), stenosis severity, plaque vulnerability features, fractional flow reserve (FFR-CT) in some centers
What it misses: Microvascular dysfunction; functional significance of intermediate stenosis (though FFR-CT addresses this)
Cost: $500–$2,000; often partially covered with appropriate indication
Radiation: 3–10 mSv (improving with newer scanners)
Time: 30–60 minutes including prep
Requires: IV contrast, beta-blocker for heart rate <65, sometimes nitroglycerin
Contrast contraindications: severe renal impairment, prior contrast reaction

CCTA has surged in clinical use over the past decade, particularly after the SCOT-HEART trial showed that CCTA-guided care reduced 5-year MI rates compared to standard care. It is now first-line in many centers for stable chest pain evaluation.

Exercise & Pharmacologic Stress Tests

Treadmill EKG stress test — cheapest stress test; sensitivity ~50–70% for obstructive CAD; useful for functional capacity assessment but limited diagnostic accuracy
Stress echo — adds wall-motion analysis; sensitivity ~80–85%; no radiation
Nuclear stress (SPECT, PET) — perfusion imaging; sensitivity ~85–90%; some radiation; PET higher resolution and lower radiation than SPECT
Stress cardiac MRI — perfusion + function; high sensitivity; no radiation; longer test, higher cost
Pharmacologic stress (dobutamine, regadenoson) — for patients who cannot exercise

Stress tests answer a functional question: is there flow-limiting ischemia? They are appropriate when symptoms suggest ischemia or when you need to confirm functional consequences of anatomic disease seen on CCTA. They are not the right primary test for asymptomatic risk stratification, where CAC outperforms.

Cardiac MRI

Best for: Cardiomyopathy evaluation, pericardial disease, cardiac mass, congenital heart disease, late gadolinium enhancement to characterize scarring
What it shows: Heart structure and function in exquisite detail; myocardial tissue characterization; viability assessment
What it misses: Direct coronary visualization (poor for stenosis evaluation)
Cost: $1,500–$3,500
Radiation: none
Time: 45–90 minutes
Requires: stillness, breath-holds, often gadolinium contrast

Cardiac MRI is not a coronary plaque test. It is a heart-muscle test. Different question, different tool.

Invasive Cardiac Catheterization

Best for: Acute coronary syndrome, high-likelihood obstructive disease where intervention may be needed in the same session, surgical planning
What it shows: Real-time coronary anatomy with the option to measure pressure gradient (FFR), perform IVUS/OCT for plaque characterization, and intervene with stenting or rotational atherectomy
Cost: $20,000+ (covered by insurance for appropriate indications)
Radiation: ~5–15 mSv
Risks: bleeding, vascular injury, contrast nephropathy, stroke (rare)
Time: 60–120 minutes; longer if intervention performed

The most invasive test; appropriate when non-invasive testing has localized significant disease and intervention is anticipated. Not a screening tool.

Lipid Markers (ApoB, Lp(a), LDL-C)

LDL-C — the conventional lipid marker; calculated or directly measured; useful for screening and treatment monitoring
ApoB — measures the number of atherogenic particles directly; outperforms LDL-C in particle-discordant patients (metabolic syndrome, T2DM, hypertriglyceridemia)
Lp(a) — genetically determined, mostly fixed across life; an independent risk factor with no proven pharmacologic treatment yet (RNA-targeted therapies in trials); crucial in family-history-of-premature-CAD patients

The lipid markers and CAC answer different questions: lipid markers describe the driving forces of atherosclerosis, CAC describes the current state of accumulated plaque. They are complementary.

Practical Decision Tree

Asymptomatic adult, primary prevention:

Annual lipid panel including ApoB if not previously done
Lp(a) once in lifetime (genetically fixed)
ASCVD risk calculator
If intermediate risk (5–19.9%) or family history of premature CAD: CAC scoring
CAC = 0: defer therapy, re-evaluate in 5–10 years
CAC 1–99: lifestyle + consider statin based on percentile
CAC 100–299: statin recommended; aggressive lifestyle
CAC ≥300: statin + reassess for stress testing or CCTA if symptoms appear

Symptomatic patient with chest pain, stable:

EKG, lipid panel, troponin if appropriate
CCTA as first-line non-invasive imaging in most centers (per SCOT-HEART, PROMISE)
Stress testing if CCTA shows intermediate stenosis or for functional confirmation
Invasive catheterization if stress positive or CCTA shows severe disease

Acute chest pain or suspected ACS:

ER evaluation, EKG, troponin
Invasive catheterization if STEMI or high-risk NSTEMI
Risk stratification with stress testing or CCTA in low-risk presentations

When CAC Isn't the Right Test

Symptomatic chest pain — CCTA or stress test, not CAC alone
Acute coronary syndrome suspected — ER evaluation, troponin, possibly cath
Known CAD on therapy — the diagnostic question is already answered; CAC adds little
Very low pretest probability — ASCVD < 5%; the CAC test rarely changes management
Patients with metal artifacts (stents, pacemakers) — image quality compromised
Elevated baseline radiation exposure concerns — though CAC's 1 mSv is modest, it's still radiation; pregnant patients should defer

Back to Table of Contents